Alkeon Capital Management - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Alkeon Capital Management ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$16,243,000
+34.1%
602,225
+19.7%
0.03%
+50.0%
Q2 2021$12,110,000
-30.7%
502,926
+24.8%
0.02%
-30.8%
Q1 2021$17,479,000
+4.9%
402,926
+0.3%
0.03%
-3.7%
Q4 2020$16,658,000401,8850.03%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
VR Adviser, LLC 3,000,000$38,190,0004.02%
Casdin Capital, LLC 1,033,811$13,160,4141.46%
BVF INC/IL 4,007,413$51,014,3671.38%
Deep Track Capital, LP 2,778,107$35,365,3021.36%
Opaleye Management Inc. 308,500$3,927,2051.28%
Eagle Health Investments LP 437,911$5,574,6071.23%
Novo Holdings A/S 1,200,000$15,276,0001.13%
RA Capital Management 4,163,211$52,997,6761.04%
VIKING GLOBAL INVESTORS LP 4,787,914$60,950,1450.25%
HighVista Strategies LLC 33,419$425,4240.20%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders